key: cord-0742115-218zlqj6
authors: Gao, Feng; Zhang, Xu
title: Pharmacokinetic profiles of a SARS‐COV‐2 neutralizing antibody BD‐604 in cynomolgus monkeys
date: 2021-07-16
journal: Drug Test Anal
DOI: 10.1002/dta.3122
sha: ab273a9074887b56e14b9dde8c4995f41a391ec1
doc_id: 742115
cord_uid: 218zlqj6

BACKGROUND: Currently, severe acute respiratory syndrome coronavirus 2 (SARS‐COV‐2) has spread worldwide as a severe pandemic and effective therapeutic medications are urgently needed. As reported previously, BD‐604 is a fully human monoclonal antibody with strong in vitro and in vivo neutralizing activity to SARS‐COV‐2. OBJECTIVE: The purpose of this study was to characterize the pharmacokinetic propertie of BD‐604 in cynomolgus monkeys. METHODS: To analyze the concentration of BD‐604 in cynomolgus monkey serum, an ELISA assay was established, and a systemic validation was performed including accuracy and precision, dilution linearity and hook effect, selectivity, specificity, stability, and parallelism tests. Then, six naïve cynomolgus monkeys (3/sex) were administered BD‐604 at a single dose of 10 mg/kg via intravenous infusion (60 min). Blood samples were collected at various time points (0–672 h) and analyzed for serum concentrations of BD‐604. RESULTS: The data from validation experiments assure the reproducibility and reliability of the established ELISA assay. Then, the validated method was used to measure BD‐604 concentration in cynomolgus monkey serum. The pharmacokinetics parameters including terminal half‐life (t(1/2)), peak serum concentration (C(max)), area under curve from time zero to last timepoint or infinity (AUC(last)/AUC(inf)), apparent volume of distribution (V(z)), clearance rate (CL), and mean residence time (MRT) were calculated and reported. BD‐604 showed no marked sex differences at the dose of 10 mg/kg when comparing the AUC(0‐last) and C(max) between female and male cynomolgus monkeys. CONCLUSION: In cynomolgus monkeys, BD‐604 possesses pharmacokinetic properties similar to natural IgGs.

population. To solve this problem, scientists and researchers contribute their efforts to discover and validate monoclonal antibodies with neutralizing activity. These antibodies possess potent and specific binding to spike protein of SARS-COV-2 and block the infection of viruses. At the same time, they could be easily produced on a large scale. As a payback of the efforts, many neutralizing antibodies have been discovered and validated to be effective in preclinical and clinical studies, [1] [2] [3] [4] [5] [6] [7] and some of them have been granted for Emergent Use Authorization by FDA. These antibodies include Regeneron's cocktail therapy casirivimab (formerly known as REGN10933) plus imdevimab (formerly REGN10987), Lilly's bamlanivimab (formerly LY-CoV555) alone and in combination with etesevimab (formerly LY-CoV016).

BD-604 is a monoclonal antibody discovered and identified by high-throughput single-cell sequencing of convalescent patients' B cells. 8, 9 The in vitro and in vivo studies revealed its potent neutralizing activity to SARS-CoV-2. 9 In this study, we determined and reported pharmacokinetic profiles of BD-604 in cynomolgus monkeys.

BD-604 was in vitro expressed using CHO-K1 cells based on the sequences determined in the previous studies. 9 The stock solution was stored at ≤À60 C. SARS-CoV-2 spike protein (RBD, His Tagged via peripheral vessels from each study animal. All blood samples were collected into commercially available non-anticoagulant centrifuge tubes. Samples were centrifuged at 4 C for 10 min at 3000  g. The samples were then aliquoted and stored at À60 C or lower until bioanalytical analysis was performed.

Serum concentrations of BD-604 were determined by using a validated ELISA method with an assay range of 10-300 ng/ml. Briefly, SARS-CoV-2 Spike protein (RBD, His Tagged, 0.5 μg/ml, 100 μl/well) 

The matrix effect of the assay was investigated by analyzing 10 lots of individual monkey serum. Individual monkey serum was tested with un-spiking and spiking of BD-604 at 10 ng/ml (LLOQ) and 240 ng/mL (HQC).

To evaluate the specificity of the method, PMS was used to obtain following samples: 2400 ng/ml human IgG, 240 ng/ml human IgG, human IgG 240 ng/ml + BD-604 240 ng/ml, human IgG 240 ng/ml + BD-604 25 ng/ml, human IgG 2400 ng/ml + BD-604 240 ng/ml, human IgG 2400 ng/ml + BD-604 25 ng/ml. Each sample was prepared for five sets.

BD-604 stock was diluted with PMS to obtain following quality control (QC) samples: ULOQ (300 ng/ml), HQC (240 ng/ml), MQC (80 ng/ml), LQC (25 ng/ml), and LLOQ (10 ng/ml). Each sample was tested in triplicate. These QC samples were used for evaluating intra-and inter-assay accuracy as well as precision of the method during six accuracy and precision runs by two analysts in 2 days.

The dilution scheme is designed to obtain hook effect samples above 

In this section, firstly, we are going to present validation data of assay method used for measurements of BD-604 concentrations in monkey serum samples. All the data met the acceptance criteria as Finally, pharmacokinetic parameters were calculated as described in Section 2 and presented below.

Ten sets of standards at concentrations of 10-300 ng/ml had been tested for method validation. The bias (%) of all samples fell within a range of À3.30%-4.50% (Table 1 ) and met the preset acceptance criteria (±25% for LLOQ and ULOQ and ±20% for other samples).

Ten lots of individual monkey serum was tested with un-spiking and spiking of BD-604 at 10 ng/ml (LLOQ) and 240 ng/ml (HQC).

The data showed that bias (%) of all samples met preset acceptance criteria (±25% for LLOQ and ±20% for HQC) as shown in 

Five sets of samples were used to determine the specificity of the assay method. As shown in Figure 2 , the method showed excellent specificity and met preset acceptance criteria (±20% for all samples).

The presence of hIgG did not interfere with the determination of BD-604 in monkey serum.

The following samples had been used for evaluating intra-and interassay accuracy as well as precision of the method: ULOQ (300 ng/ml), HQC (240 ng/ml), MQC (80 ng/ml), LQC (25 ng/mL), and LLOQ (10 ng/ml). The data had been summarized in Table 2 , and all results met preset acceptance criteria (accuracy and precision, ±25% for ULOQ/LLOQ, and ±20% for others; total error, ±40% for ULOQ/ LLOQ and ±30% for others).

Dilution linearity and hook effect were determined, and the data were presented in Figure 3 . No obvious hook effect was observed even when the concentration of BD-604 was up to 200 μg/ml, suggesting that preset acceptance criteria was met (±20% for all samples).

The stability of BD-604 in serum samples was investigated under various conditions, and the data were listed in Table 3 . All results met preset acceptance criteria (±20% for all samples). Table 4 .

No mortality or morbidity was observed throughout the study. No BD-604 related changes in hematology or serum chemistry were noted (data not shown here).

Following single IV infusion administration of BD-604 at 10 mg/kg in male and female monkeys, mean serum concentrations of BD-604 were shown in Figure 4 and pharmacokinetic parameters were listed in Table 5 

In this study, we established and validated an ELISA method for determination of BD-604 in monkey serum. The method demonstrated excellent sensitivity, specificity, selectivity, accuracy and T A B L E 2 Intra-assay and inter-assay accuracy and precision of the assay method used for determination of serum concentrations of BD-604 

Abbreviations: CV, coefficient variance; TE, total error. (Tables 1 and 2 and 4 and Figures 1-3) . Taking tested dilution factor and range of standards into the consideration, this method is enough for determination of BD-604 at high concentrations such as $300 μg/ml ($Cmax). For long-term stability (Table 3) , we stored BD-604 samples at ≤À60 C for 33 days, which is enough to cover the duration of both PK sampling (0-673 h) and following sample analysis/reanalysis.

Since the validation studies met all the preset acceptance criteria, the method was used to analyze BD-604 concentrations in monkey serum samples. As shown in Table 5 and Figure 4 , the data suggested 

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail

LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

A neutralizing monoclonal antibody for hospitalized patients with Covid-19

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells

Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy

Bioanalytical Method Validation" draft guidance, U.S. Department of Health and Human Services, Food and Drug Administration

ICH Harmonised Guideline: Bioanalytical Method Validation M10, Draft version

Pharmacokinetic properties of humanized IgG1 and IgG4 antibodies in preclinical species: translational evaluation

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys

Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human

Safety and efficacy of monoclonal antibody VIS410 in adults with uncomplicated influenza A infection: results from a randomized, double-blind, phase-2, placebocontrolled study

Interstitial IgG antibody pharmacokinetics assessed by combined in vivo-and physiologically-based pharmacokinetic modelling approaches

Pharmacokinetic profiles of a SARS-COV-2 neutralizing antibody BD-604 in cynomolgus monkeys

The experiments were performed and completed by Joinn Laboratories, Inc. We would like to thank the colleagues of Joinn Laboratories for their significant contributions in this study. This work was supported, in part, by Beijing Municipal Science and Technology Project (no. Z201100007920018).

The authors confirm that this article content has no conflict of interest.

Data available on request from the authors: The data that support the findings of this study are available from the corresponding author upon reasonable request.

https://orcid.org/0000-0001-8688-5126